364 related articles for article (PubMed ID: 29673870)
1. Microstructural alterations in the onychomycotic and psoriatic nail: Relevance in drug delivery.
Cutrín Gómez E; Anguiano Igea S; Delgado-Charro MB; Gómez Amoza JL; Otero Espinar FJ
Eur J Pharm Biopharm; 2018 Jul; 128():48-56. PubMed ID: 29673870
[TBL] [Abstract][Full Text] [Related]
2. The dermatopharmacologic profile of ciclopirox 8% nail lacquer.
Bohn M; Kraemer K
J Am Podiatr Med Assoc; 2000; 90(10):491-4. PubMed ID: 11107709
[TBL] [Abstract][Full Text] [Related]
3. Transungual delivery of terbinafine by iontophoresis in onychomycotic nails.
Nair AB; Vaka SR; Murthy SN
Drug Dev Ind Pharm; 2011 Oct; 37(10):1253-8. PubMed ID: 21457120
[TBL] [Abstract][Full Text] [Related]
4. Transungual delivery of efinaconazole: its deposition in the nail of onychomycosis patients and in vitro fungicidal activity in human nails.
Sakamoto M; Sugimoto N; Kawabata H; Yamakawa E; Kodera N; Pillai R; Tatsumi Y
J Drugs Dermatol; 2014 Nov; 13(11):1388-92. PubMed ID: 25607707
[TBL] [Abstract][Full Text] [Related]
5. Dermatopharmacology of ciclopirox nail lacquer topical solution 8% in the treatment of onychomycosis.
Bohn M; Kraemer KT
J Am Acad Dermatol; 2000 Oct; 43(4 Suppl):S57-69. PubMed ID: 11051135
[TBL] [Abstract][Full Text] [Related]
6. Ultrastructural changes in onychomycosis during the treatment with bifonazole/urea ointment.
Fritsch H; Stettendorf S; Hegemann L
Dermatology; 1992; 185(1):32-6. PubMed ID: 1386263
[TBL] [Abstract][Full Text] [Related]
7. Understanding the formidable nail barrier: A review of the nail microstructure, composition and diseases.
Baswan S; Kasting GB; Li SK; Wickett R; Adams B; Eurich S; Schamper R
Mycoses; 2017 May; 60(5):284-295. PubMed ID: 28098391
[TBL] [Abstract][Full Text] [Related]
8. Development of ciclopirox nail lacquer with enhanced permeation and retention.
Thapa RK; Choi JY; Go TG; Kang MH; Han SD; Jun JH; Son MW; Yong CS; Kim JO
Arch Pharm Res; 2016 Jul; 39(7):953-9. PubMed ID: 27306785
[TBL] [Abstract][Full Text] [Related]
9. Human nail plate modifications induced by onychomycosis: implications for topical therapy.
Baraldi A; Jones SA; Guesné S; Traynor MJ; McAuley WJ; Brown MB; Murdan S
Pharm Res; 2015 May; 32(5):1626-33. PubMed ID: 25416028
[TBL] [Abstract][Full Text] [Related]
10. Visualisation of penetration of topical antifungal drug substances through mycosis-infected nails by matrix-assisted laser desorption ionisation mass spectrometry imaging.
Endringer Pinto F; Bagger C; Kunze G; Joly-Tonetti N; Thénot JP; Osman-Ponchet H; Janfelt C
Mycoses; 2020 Aug; 63(8):869-875. PubMed ID: 32406142
[TBL] [Abstract][Full Text] [Related]
11. An investigation of how fungal infection influences drug penetration through onychomycosis patient's nail plates.
McAuley WJ; Jones SA; Traynor MJ; Guesné S; Murdan S; Brown MB
Eur J Pharm Biopharm; 2016 May; 102():178-84. PubMed ID: 26969264
[TBL] [Abstract][Full Text] [Related]
12. Optimized Ciclopirox-Based Eudragit RLPO Nail Lacquer: Effect of Endopeptidase Enzyme as Permeation Enhancer on Transungual Drug Delivery and Efficiency Against Onychomycosis.
Khattab A; Shalaby S
AAPS PharmSciTech; 2018 Apr; 19(3):1048-1060. PubMed ID: 29138987
[TBL] [Abstract][Full Text] [Related]
13. Ciclopirox delivery into the human nail plate using novel lipid diffusion enhancers.
Hafeez F; Hui X; Selner M; Rosenthal B; Maibach H
Drug Dev Ind Pharm; 2014 Jun; 40(6):838-44. PubMed ID: 23600655
[TBL] [Abstract][Full Text] [Related]
14. In Vitro penetration of a novel oxaborole antifungal (AN2690) into the human nail plate.
Hui X; Baker SJ; Wester RC; Barbadillo S; Cashmore AK; Sanders V; Hold KM; Akama T; Zhang YK; Plattner JJ; Maibach HI
J Pharm Sci; 2007 Oct; 96(10):2622-31. PubMed ID: 17621679
[TBL] [Abstract][Full Text] [Related]
15. Ultrasound Assessment of Psoriatic Onychopathy: A Cross-sectional Study Comparing Psoriatic Onychopathy with Onychomycosis.
Moreno M; Lisbona MP; Gallardo F; Deza G; Ferran M; Pontes C; Luelmo J; Maymó J; Gratacós J
Acta Derm Venereol; 2019 Feb; 99(2):164-169. PubMed ID: 30281142
[TBL] [Abstract][Full Text] [Related]
16. Efinaconazole topical solution, 10%: formulation development program of a new topical treatment of toenail onychomycosis.
Bhatt V; Pillai R
J Pharm Sci; 2015 Jul; 104(7):2177-82. PubMed ID: 25940933
[TBL] [Abstract][Full Text] [Related]
17. Onychomycosis: Current Understanding and Strategies for Enhancing Drug Delivery into Human Nail Tissue.
Aslam R; Hussain T; Yousaf AM; Ghori MU; Khan IU; Rizvi SAA; Shahzad Y
Curr Drug Res Rev; 2021; 13(1):25-35. PubMed ID: 32735534
[TBL] [Abstract][Full Text] [Related]
18. The Presence of an Air Gap Between the Nail Plate and Nail Bed in Onychomycosis Patients: Treatment Implications for Topical Therapy.
Gupta AK; Pillai R
J Drugs Dermatol; 2015 Aug; 14(8):859-63. PubMed ID: 26267730
[TBL] [Abstract][Full Text] [Related]
19. Access of efinaconazole topical solution, 10%, to the infection site by spreading through the subungual space.
Elewski BE; Pollak RA; Pillai R; Olin JT
J Drugs Dermatol; 2014 Nov; 13(11):1394-8. PubMed ID: 25607708
[TBL] [Abstract][Full Text] [Related]
20. Ciclopirox vs amorolfine: in vitro penetration into and permeation through human healthy nails of commercial nail lacquers.
Monti D; Tampucci S; Chetoni P; Burgalassi S; Mailland F
J Drugs Dermatol; 2014 Feb; 13(2):143-7. PubMed ID: 24509963
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
